Nephrotic syndrome under treatment with dasatinib: Be aware of a possible adverse drug reaction

A. H.G. Muller-Hansma, J. van Der Lugt, C. M. Zwaan

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

8 Citaten (Scopus)


The protein kinase inhibitor dasatinib, targeting BCR-ABL and Src family kinases, is used in chronic myeloid leukaemia and Philadelphia-chromosome positive acute lymphoblastic leukaemia. The Netherlands Pharmacovigilance Centre Lareb has received one report of nephrotic syndrome associated with the use of dasatinib. With some other protein kinase inhibitors, targeting vascular endothelial growth factor, nephrotic syndrome is a well-known adverse drug reaction. The Dutch and European pharmacovigilance databases and scientific literature contain several cases indicating a causal relationship between dasatinib and nephrotic syndrome. Nephrotic syndrome was recently added to the list of adverse drug reactions in the Dutch summary of product characteristics for dasatinib. It is important to recognise the possibility of this adverse drug reaction when a patient develops nephrotic syndrome under treatment with dasatinib.

Originele taal-2Engels
Pagina's (van-tot)428-431
Aantal pagina's4
TijdschriftNetherlands Journal of Medicine
Nummer van het tijdschrift10
StatusGepubliceerd - dec. 2017
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Nephrotic syndrome under treatment with dasatinib: Be aware of a possible adverse drug reaction'. Samen vormen ze een unieke vingerafdruk.

Citeer dit